. Overall, high Zva was found in 42% of all AS patients.
Patients with high Zva were significantly older (p<0.0001), and more often female (p< 0.0001), they had significantly smaller aortic valve area (p<0.0001), higher mean gradient (p=0.001), lower indexed stroke volume (p<0.0001) and cardiac output (p<0.0001), significantly higher LVED filling pressures (p=0.03), systolic pulmonary artery pressure (p=0.0005), higher capillary wedge pressure(p=0.006), reduced systemic arterial compliance (p<0.0001), but higher systemic vascular resistances(p<0.0001).
Ten-year survival was significantly reduced in patients with higher Zva (50±5%) as compared to those with lower Zva (67±3%; p=0.01). After adjustment for all other risk factors, Zva was independently associated with reduced long-term survival (hazard ratio [HR] =1.12 95% CI: 1.009-1.22; p=0.03). Of interest, high Zva remains associated with reduced survival as compared to low Zva, in patients with normal LV stroke volume, but was no longer significant in low flow patients (>60mL: 49±8vs. 69±4%, p=0.012; ≤60mL: 49±7 vs. 53±13%, p=0.96).
Conclusion:
In this large cardiac catheterization-based study, high Zva estimated invasively is frequent in patients with severe AS, and appears as a robust and independent predictor of survival.
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Marfan syndrome diagnosed during childhood: focus on cardiac events in the French database Sébastien Hascoët (1), Yves Dulac (2), Jean-Bernard Ruidavets (3), Thomas Edouard (4), Florence Arnoult (5), Bertrand Chevallier (6), Olivier Milleron (5), Laurence Olivier-Faivre (7), Bruno Leheup (8), Sylvie Odent (9), Sophie Dupuis-Girod (10), Cécile Zordan (11), Nicole Philip (12), Chantal Stheneur (6), Philippe Acar (2), Jean Ferrière (3), Guillaume Jondeau (5 Life expectancy of patients with Marfan syndrome has increased, due to earlier diagnosis, better familial screening, regular follow-up (FU) and timely prophylactic aortic surgery (PASu). Incidence of aortic events in affected patients recognized during childhood is unknown.
Methods: 465 patients with Marfan syndrome, diagnosed before 18 yearold between 1993 and 2013 were included in the French multicenter database. Cardio-vascular events (death, aortic dissection or PASu) were recorded Results: FU was complete for 69.5%. A cardio-vascular event occurred in 25 patients (5.4% 95CI 3.5-7.8%), including PASu (n=20, 4.3% 95CI 2.5-6.2%), aortic dissection (n=3, 0.6% 95CI 0.0-1.4%) and deaths (n=2, 0.4% 95CI 0.0-1.0%). 16 events (64%) occurred before 19 year-old (Median 15.0, min 2.8, interquartile 11.7-16.3; PASu n=12, deaths n=2 and dissection n= 2). One sudden death occurred in a 18 y.o. girl followed until the age of 14.3 under betablockade treatment. A 3.4 year-old boy with a FBN1 mutation diagnosed at the age of 1.1 died from respiratory distress and viral myocarditis.
An aortic surgery was performed in 23 patients (4.9%, 95CI 3.0-6.9%), including a Bentall procedure with mechanical aortic valve in 10 (43.5%), a valve sparing surgery in the remaining 13 (56.5%) and a supra-coronary graft in 4 (17.4%, dissection: n=2 and PASu: n=2). Mean age at the date of PASu was 17.1±6.5 year-old Events occurred before or at inclusion in the database in 8 patients (32.0%) (PASu n=5, dissection n=2, death n=1). Dissection was observed before inclusion in 2 patients out of 3 and during pregnancy in 1 patient aged 25 and lost of FU until 19 year-old. Kaplan-Meier survival estimate indicates that 95% of patients remained free from events at eighteen and 78% at thirty year-old.
Conclusion:
Prophylactic surgery for enlarged aorta is the main cause of cardiac events in patients with Marfan syndrome diagnosed during childhood. A quarter of them have a cardiac event before thirty year-old (figure next page). Infective endocarditis (IE) is a severe disease, with an in-hospital mortality around 20%. 10% of the patients will have another episode of IE. Thus, looking for and treating the portal of entry of IE is particularly important. Yet, literature on this topic is nonexistent.
Since January 2005, we have been prospectively enrolling patients hospitalized for certain IE (Duke-Li criteria) in the International Collaboration on Endocarditis database. Since then, we have been systematically looking for and treating the portal of entry of the present IE episode and potential portals of entry of a new IE episode.
Among 444 patients hospitalized in our institution between 2005 and 2011, 318 were included in the present study (exclusion of patients who died during hospitalization; some medical charts unavailable for technical reasons).
Portal of entry of the present IE episode was identified in 238 patients (74%). Distribution of identified portals of entry was: cutaneous: 44% (healthcare-associated: 21%; community-acquired: 13%; IV drug use: 9%); oral / dental: 29%; gastrointestinal: 22%; genitourinary: 3%; ENT: 2%; respiratory: 1%.
Potential portals of entry were: continuation of IV drug use in 21 patients and a cutaneous disease in 2 patients; oral / dental infective foci in 66 / 125 patients with stomatologic examination; colonic lesions (polyps, diverticulosis, adenocarcinoma) in 32 / 80 patients in whom colonoscopy was performed because they were ≥50 years old or they had a familial history of colonic polyposis; genitourinary lesions (prostatic cancer or hyperplasia, urethral stenosis...) in 32 / 52 patients with genitourinary examination; ENT lesions (sinusitis, otomastoidosis...) in 6 / 180 examinations.
In conclusion, systematic search for the portal of entry of IE was successful in as many as ¾ of patients. Systematically searching for a potential oral / dental, gastrointestinal or genitourinary portal of entry of a new IE episode was also successful in a lot of patients.
